A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial
Recruiting · NCT07754175 · Observational (researchers observe without assigning treatment) · Lead sponsor: Kang Stem Biotech Co., Ltd.
View the official record on ClinicalTrials.gov →What this trial is about
A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Participants who received placebo in the K0701 clinical trial and completed the Long-term follow-up study
- Participants who voluntarily provide written informed consent to participate in this extension study
Exclusion criteria
- Participants meeting any of the following criteria:
- Participants whom the investigator considers unsuitable for participation in this extension study.
- Pregnant or breastfeeding women, and women of childbearing potential or men who do not agree to use an appropriate method of contraception during the study
Where it is running
2 locations listed.
- CHA University Bundang Medical Center - Seoul, South Korea
- Kyung Hee University Hospital - Seoul, South Korea